Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of RGX-121 in Children 5 Years of Age and Older With MPS II (Hunter Syndrome)

NCT04571970 is registered in ClinicalTrials.gov with REGENXBIO Inc. as lead sponsor.

NCT NCT04571970
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04571970 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of RGX-121 in Children 5 Years of Age and Older With MPS II (Hunter Syndrome)
Lead sponsor
REGENXBIO Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
March 11, 2021
Completion date
May 23, 2024
Enrollment
6 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

mucopolysaccharidosis type ii (mps ii)